Key result
This editorial introduces a special issue on congestive heart failure, discussing the pathophysiologic role of the renin-angiotensin-aldosterone system and the cardiorenal axis in disease progression.
Answers are grounded in this paper and cite their sources.
This editorial introduces a special issue on congestive heart failure, highlighting the pathophysiologic role of the renin-angiotensin-aldosterone system and the cardiorenal axis in sodium retention and disease progression.
The aging of our society has made heart failure one of our major health problems, straining our nation's health care system and economy. What begins with the failing heart, expressed as systolic and/or diastolic ventricular dysfunction, can eventuate in a clinical syndrome, congestive heart failure (CHF), with characteristic symptoms and signs. Not all patients with heart failure have CHF. The pathophysiologic origins of CHF are rooted in salt-avid kidneys, which become adversaries of the heart, lungs, and liver—a house divided. Salt and water retention in CHF is mediated by activation of the renin-angiotensin-aldosterone system (RAAS). It has been argued that the RAAS evolved with terrestrial life and the associated need to retain salt and water during periods of deprivation or in response to intravascular volume contraction that accompanies blood loss, vomiting, or diarrhea. In the presence of normal dietary salt and water intake and intravascular volume, as is the case in heart failure, RAAS activation proves pathologic—circulatory homeostasis gone awry. Volpe et al.1–3 and Magri et al.4 have shown, even in the early stages, prior to the appearance of signs and symptoms of salt and water retention, the reduction in renal vasodilator and functional reserves, which translates into impairment in sodium excretion during acute or chronic sodium loading. The impairment in renal functional reserve has been attributed to enhanced proximal tubular sodium resorption mediated by angiotensin II. It is reversed by angiotensin-converting enzyme (ACE) inhibition or angiotensin II type 1 (AT1) receptor antagonism. Given that the circulating RAAS is not yet activated under basal (or resting) conditions in early heart failure, local elevation of angiotensin II and an imbalance with its physiologic antagonists—nitric oxide, bradykinin, and prostaglandins—have been held responsible. It can also be argued that intermittent RAAS activation, such as occurs with upright posture (with or without ambulation), may be involved in altering functional reserve in early heart failure. In either case, ACE inhibitor treatment is a mainstay in both asymptomatic (compensated) and symptomatic (decompensated) heart failure. Despite such therapy (with or without loop diuretics), recurrent bouts of symptomatic heart failure appear and often require hospitalization. Symptomatic heart failure is this country's most common cause of hospitalization, particularly among the elderly. In such patients, quality of life is seriously compromised despite today's standard of care, which includes an ACE inhibitor and loop diuretic. Recurrent bouts of symptomatic failure disrupt the apparent clinical compensation established by what had appeared to be an optimal regimen of these agents. Insight into their origins may be gleaned from historical accounts provided by these patients. For example, they often report a worsening of symptomatic heart failure during the evening after a day filled with physical activities, and on the following day. They likewise note less dramatic diuresis in response to their previously effective furosemide regimen on the day after such activities, or when the diuretic is taken during the day filled with ambulation. This is not refractory heart failure; it is not an indication for cardiac transplantation. Indeed, on days when patients are more sedentary, they report on the efficacy of the diuretic regimen; the diuresis is such that it may confine them to their residence for several hours. The diuretic may even have been voluntarily suspended to avoid embarrassment during social functions. What, then, accounts for such episodes of decompensation? Reduction in ventricular performance secondary to cardiac factors (e.g., a decline in myocardial contractility due to ischemia and/or infarction, worsened mitral or tricuspid apparatus dysfunction with valvular incompetence, or the appearance of atrial fibrillation) can often be excluded. Extracardiac factors need to be considered, and this leads us to the cardiorenal axis and sodium avidity promoted by effector hormones of the RAAS. Angiotensin II and aldosterone both have diverse portfolios of adverse actions. These include their effects on classic target tissues, such as epithelial cells of the proximal and distal nephron and colon, sweat, and salivary glands, and their influence on the tonicity of renal efferent and systemic arterioles. They overpower the body's endogenous natriuretic peptides, leading to a positive sodium balance (i.e., sodium retention). Chronic elevations in circulating angiotensin II and aldosterone also have effects on nonclassic tissues. For example, they promote vascular remodeling. This includes abnormal vasomotor reactivity and baroreceptor responsiveness secondary to dysfunctional endothelium and oxidative stress; an imbalance between sympathetic and parasympathetic nervous systems, including impaired neuronal uptake of catecholamines; and an adverse accumulation of connective tissue within the perivascular spaces of small arteries and arterioles of the heart, kidneys, and other systemic organs that compromises their reactivity. Finally, these hormones promote a proinflammatory state that involves elevations of such cytokines as tumor necrosis factor-α, which compromises ventricular function and promotes a catabolic state that may eventuate in a wasting syndrome termed cardiac cachexia. A distinguished group of investigators have freely given of their time to address these topics in this issue of Congestive Heart Failure. The information they provide broadens the perspective of CHF and brings its less well recognized features to practicing physicians. It has been a privilege to serve as Guest Editor.
No takes yet. Share an insight, caveat, or question.
Karl T. Weber (2002) conducted an editorial in Congestive Heart Failure. This editorial introduces a special issue on congestive heart failure, discussing the pathophysiologic role of the renin-angiotensin-aldosterone system and the cardiorenal axis in disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: